Twist Bioscience officer sells 14,205 shares

Twist Bioscience Corp officer Dennis Cho reported an open-market sale of Common Stock.

(Very High)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Twist Bioscience Corp officer Dennis Cho reported an open-market sale of Common Stock. On June 24, 2026, Cho sold 14,205 shares at $89.75 per share. After this transaction, he continues to hold 105,141 shares directly.

The filing notes that this sale was carried out under a previously adopted Rule 10b5-1 trading plan dated February 17, 2026, indicating the trade was pre-planned rather than timed at discretion, which often signals routine portfolio management rather than a change in outlook.

Insider Trade Summary 10b5-1

Net Seller: 14,205 shares

Net Sell 1 txn

Insider Cho Dennis

Role See Remarks

Sold 14,205 shs ($1.27M)

Type	Security	Shares	Price	Value
Sale	Common Stock	14,205	$89.75	$1.27M

Holdings After Transaction: Common Stock — 105,141 shares (Direct)

Footnotes (1)

F1. The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 17, 2026.

Key Figures

Shares sold: 14,205 shares Sale price per share: $89.75 per share Shares held after transaction: 105,141 shares +3 more

6 metrics

Shares sold 14,205 shares Open-market sale on June 24, 2026

Sale price per share $89.75 per share Common Stock transaction

Shares held after transaction 105,141 shares Direct ownership following sale

Net shares sold 14,205 shares Net-sell direction in transaction summary

Transaction date June 24, 2026 Date of open-market sale

Trading plan adoption date February 17, 2026 Rule 10b5-1 plan adoption

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, net-sell direction

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"The transaction action is classified as an open-market sale of Common Stock."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"The reported transaction involves Common Stock of Twist Bioscience Corp."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

net-sell direction financial

"The transaction summary shows a net-sell direction of 14,205 shares."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Twist Bioscience (TWST) report for Dennis Cho?

Twist Bioscience officer Dennis Cho reported selling 14,205 shares of Common Stock. The sale occurred on June 24, 2026, as an open-market transaction under a pre-established Rule 10b5-1 trading plan adopted on February 17, 2026.

At what price did Dennis Cho sell Twist Bioscience (TWST) shares?

Dennis Cho sold 14,205 Twist Bioscience Common Stock shares at $89.75 per share. This price reflects the average sale price reported for the open-market transaction executed on June 24, 2026, under his Rule 10b5-1 trading plan.

How many Twist Bioscience (TWST) shares does Dennis Cho hold after the sale?

After the reported sale, Dennis Cho directly holds 105,141 shares of Twist Bioscience Common Stock. This post-transaction balance, shown in the filing, helps investors gauge the relative size of the sale compared with his remaining ownership stake.

Was the Dennis Cho sale of Twist Bioscience (TWST) shares pre-planned?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2026. Such plans pre-schedule trades, suggesting the timing reflects a preset program rather than a new, discretionary decision.

What does a Rule 10b5-1 trading plan mean for Twist Bioscience (TWST) insider trades?

A Rule 10b5-1 trading plan allows insiders to pre-arrange stock trades while not in possession of material nonpublic information. For Twist Bioscience, Cho’s sale under such a plan indicates a structured, pre-planned transaction rather than opportunistic market timing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/26/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cho Dennis

(Last)

(First)

(Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/24/2026		S		14,205⁽¹⁾	D	$89.75	105,141	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 17, 2026.

Remarks:

Senior Vice President, Chief Legal Officer & Corporate Secretary

	/s/ Judy Yan, as Attorney-in-Fact for Dennis Cho	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR